SEC Form S-8 POS filed by Paratek Pharmaceuticals Inc.

$PRTK
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $PRTK alert in real time by email
S-8 POS 1 d556744ds8pos.htm S-8 POS S-8 POS

As filed with the Securities and Exchange Commission on September 21, 2023

Registration No. 333-135506

Registration No. 333-150869

Registration No. 333-157927

Registration No. 333-157929

Registration No. 333-160222

Registration No. 333-164468

Registration No. 333-172041

Registration No. 333-180517

Registration No. 333-187254

Registration No. 333-194624

Registration No. 333-201204

Registration No. 333-205482

Registration No. 333-210053

Registration No. 333-217660

Registration No. 333-218847

Registration No. 333-224781

Registration No. 333-226507

Registration No. 333-228218

Registration No. 333-230097

Registration No. 333-237084

Registration No. 333-254857

Registration No. 333-263579

Registration No. 333-270646

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-135506

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-150869

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-157927

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-157929

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-160222

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-164468

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-172041

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-180517

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-187254

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-194624

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-201204

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-205482

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-210053

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-217660

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-218847

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-224781

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-226507

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-228218

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-230097

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-237084

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-254857

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-263579

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-270646

 

 

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

PARATEK PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   33-0960223
(State or other jurisdiction of
incorporation or organization)
 

(IRS employer

identification number)

75 Park Plaza

Boston, Massachusetts 02116

(617) 807-6600

(Address of principal executive offices)

Novacea, Inc. 2006 Incentive Award Plan

Amended 2001 Stock Option Plan of Novacea, Inc.

2006 Incentive Award Plan

Amended and Restated 2002 Stock Option Plan

2009 Employee Stock Purchase Plan

2006 Incentive Award Plan (Amended and Restated effective June 2, 2010)

Paratek Pharmaceuticals, Inc. 2014 Equity Incentive Plan, As Amended

Paratek Pharmaceuticals, Inc. 2006 Incentive Award Plan, as amended and restated

Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan

Paratek Pharmaceuticals, Inc. 2015 Inducement Plan

Paratek Pharmaceuticals, Inc. 2017 Inducement Plan

Paratek Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan

Paratek Pharmaceuticals, Inc. 2017 Inducement Plan, as amended

(Full title of the Plans)

Evan Loh, M.D.

Chief Executive Officer

Paratek Pharmaceuticals, Inc.

75 Park Plaza

Boston, Massachusetts 02116

(617) 807-6600

(Name and address of Agent for Service)

(617) 807-6600

(Telephone number, including area code, of agent for Service)

Copies to:

Peter N. Handrinos

Leah R. Sauter

Elisabeth M. Martin

Latham & Watkins LLP

200 Clarendon Street

Boston, MA 02116

(617) 880-4500

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer, “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer      Accelerated filer  
Non-accelerated filer      Smaller reporting company  
     Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

 

 

 


DEREGISTRATION OF SECURITIES

These Post-Effective Amendments (these “Post-Effective Amendments”) filed by Paratek Pharmaceuticals, Inc., a Delaware corporation (the “Registrant”), deregister all shares of the Registrant’s common stock, par value $0.001 per share (the “Shares”), that remain unissued under the following Registration Statements on Form S-8 (each, a “Registration Statement”, and collectively, the “Registration Statements”) filed by the Registrant with the U.S. Securities and Exchange Commission (the “SEC”):

 

   

Registration Statement on Form S-8 (No. 333-135506) pertaining to the registration of an aggregate of 4,426,413 Shares, issuable under the Registrant’s Novacea, Inc. 2006 Incentive Award Plan and Amended 2001 Stock Option Plan of Novacea, Inc., which was filed with the SEC on June 30, 2006.

 

   

Registration Statement on Form S-8 (No. 333-150869) pertaining to the registration of 1,320,937 Shares, issuable under the Registrant’s Novacea, Inc. 2006 Incentive Award Plan, which was filed with the SEC on May 13, 2008.

 

   

Registration Statement on Form S-8 (No. 333-157927) pertaining to the registration of 258,344 Shares, issuable under the Registrant’s 2006 Incentive Award Plan, which was filed with the SEC on March 13, 2009.

 

   

Registration Statement on Form S-8 (No. 333-157929) pertaining to the registration of 1,043,775 Shares, issuable under the Registrant’s Amended and Restated 2002 Stock Option Plan, which was filed with the SEC on March 13, 2009.

 

   

Registration Statement on Form S-8 (No. 333-160222) pertaining to the registration of an aggregate of 500,000 Shares, issuable under certain of the Registrant’s 2009 Employee Stock Purchase Plan, which was filed with the SEC on June 25, 2009.

 

   

Registration Statement on Form S-8 (No. 333-164468) pertaining to the registration of an aggregate of 400,000 Shares, issuable under certain of the Registrant’s 2006 Incentive Award Plan, which was filed with the SEC on January 22, 2010.

 

   

Registration Statement on Form S-8 (No. 333-172041) pertaining to the registration of 1,422,488 Shares, issuable under the Registrant’s 2006 Incentive Award Plan (Amended and Restated effective June 2, 2010), which was filed with the SEC on February 3, 2011.

 

   

Registration Statement on Form S-8 (No. 333-180517) pertaining to the registration of an aggregate of 695,225 Shares, issuable under certain of the Registrant’s 2006 Incentive Award Plan, which was filed with the SEC on April 2, 2012.

 

   

Registration Statement on Form S-8 (No. 333-187254) pertaining to the registration of an aggregate of 933,819 Shares, issuable under certain of the Registrant’s 2006 Incentive Award Plan, which was filed with the SEC on March 14, 2013.

 

   

Registration Statement on Form S-8 (No. 333-194624) pertaining to the registration of an aggregate of 942,119 Shares, issuable under certain of the Registrant’s 2006 Incentive Award Plan, which was filed with the SEC on March 17, 2014.

 

   

Registration Statement on Form S-8 (No. 333-201204) pertaining to the registration of an aggregate of 757,402 Shares, issuable under certain of the Registrant’s 2014 Equity Incentive Plan, as amended, which was filed with the SEC on December 22, 2014.

 

   

Registration Statement on Form S-8 (No. 333-205482) pertaining to the registration of an aggregate of 1,679,640 Shares, issuable under certain of the Registrant’s 2006 Incentive Award Plan, as amended and restated, 2015 Equity Incentive Plan, and 2015 Inducement Plan which was filed with the SEC on July 2, 2015.


   

Registration Statement on Form S-8 (No. 333-210053) pertaining to the registration of an aggregate of 880,430 Shares, issuable under certain of the Registrant’s 2015 Equity Incentive Plan, which was filed with the SEC on March 9, 2016.

 

   

Registration Statement on Form S-8 (No. 333-217660) pertaining to the registration of an aggregate of 1,167,931 Shares, issuable under certain of the Registrant’s 2015 Equity Incentive Plan, which was filed with the SEC on May 4, 2017.

 

   

Registration Statement on Form S-8 (No. 333-218847) pertaining to the registration of an aggregate of 550,000 Shares, issuable under certain of the Registrant’s 2017 Inducement Plan, which was filed with the SEC on June 20, 2017.

 

   

Registration Statement on Form S-8 (No. 333-224781) pertaining to the registration of an aggregate of 1,397,050 Shares, issuable under certain of the Registrant’s 2015 Equity Incentive Plan, which was filed with the SEC on May 9, 2018.

 

   

Registration Statement on Form S-8 (No. 333-226507) pertaining to the registration of an aggregate of 943,294 Shares, issuable under certain of the Registrant’s 2018 Employee Stock Purchase Plan, which was filed with the SEC on August 2, 2018.

 

   

Registration Statement on Form S-8 (No. 333-228218) pertaining to the registration of an aggregate of 500,000 Shares, issuable under certain of the Registrant’s 2017 Inducement Plan, as amended, which was filed with the SEC on November 6, 2018.

 

   

Registration Statement on Form S-8 (No. 333-230097) pertaining to the registration of an aggregate of 1,612,969 Shares, issuable under certain of the Registrant’s 2015 Equity Incentive Plan, which was filed with the SEC on March 6, 2019.

 

   

Registration Statement on Form S-8 (No. 333-237084) pertaining to the registration of an aggregate of 1,991,387 Shares, issuable under certain of the Registrant’s 2015 Equity Incentive Plan, which was filed with the SEC on March 11, 2020.

 

   

Registration Statement on Form S-8 (No. 333-254857) pertaining to the registration of an aggregate of 2,325,828 Shares, issuable under certain of the Registrant’s 2015 Equity Incentive Plan, which was filed with the SEC on March 30, 2021.

 

   

Registration Statement on Form S-8 (No. 333-263579) pertaining to the registration of an aggregate of 3,335,590 Shares, issuable under certain of the Registrant’s 2015 Equity Incentive Plan and 2017 Inducement Plan, as amended, which was filed with the SEC on March 15, 2022.

 

   

Registration Statement on Form S-8 (No. 333-270646) pertaining to the registration of an aggregate of 2,832,577 Shares, issuable under certain of the Registrant’s 2015 Equity Incentive Plan, which was filed with the SEC on March 17, 2023.

Pursuant to an Agreement and Plan of Merger (the “Merger Agreement”), dated as of June 6, 2023, among the Registrant, Resistance Acquisition, Inc., a Delaware corporation (“Parent”), and Resistance Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), Merger Sub was merged with and into the Registrant (the “Merger”), with the Registrant continuing as the surviving corporation and a wholly owned subsidiary of Parent. The Merger became effective on September 21, 2023.

In connection with the closing of the Merger, the offerings pursuant to the Registration Statements have been terminated. In accordance with undertakings made by the Registrant in the Registration Statements to remove from registration, by means of a post-effective amendment, any of the securities that remain unsold at the termination of the offerings, the Registrant hereby removes from registration all Shares registered under the Registration Statements but not sold under the Registration Statements.


The foregoing description of the Merger, the Merger Agreement and the transactions contemplated thereby does not purport to be complete and is subject to, and qualified in its entirety by, the Merger Agreement, which is attached as Exhibit 2.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on June 7, 2023.


SIGNATURE

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boston, Commonwealth of Massachusetts, on September 21, 2023.

 

PARATEK PHARMACEUTICALS, INC.
By:   /s/ Evan Loh
  Name: Evan Loh, M.D.
  Title: Chief Executive Officer

No other person is required to sign this Post-Effective Amendment in reliance upon Rule 478 under the Securities Act of 1933, as amended.

Get the next $PRTK alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$PRTK

DatePrice TargetRatingAnalyst
5/2/2023$7.00 → $5.00Buy
Jefferies
4/17/2023$24.00Buy
BTIG Research
2/10/2022$11.00Buy → Strong Buy
WBB Securities
11/9/2021$28.00 → $27.00Buy
HC Wainwright & Co.
More analyst ratings

$PRTK
Press Releases

Fastest customizable press release news feed in the world

See more
  • Gurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc.

    CAMBRIDGE, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Gurnet Point Capital ("Gurnet Point") and Novo Holdings A/S ("Novo Holdings") announced today the completion of their acquisition of Paratek Pharmaceuticals, Inc. ("Paratek" or the "Company") (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats. The Company's lead commercial product, NUZYRA® (omadacycline), is a once-daily oral and intravenous antibiotic available in the United States for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structu

    $PRTK
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Paratek Pharmaceuticals Announces Stockholder Approval of Acquisition by Gurnet Point Capital and Novo Holdings A/S

    BOSTON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. ("Paratek") (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats, today announced, based on a preliminary vote count, that stockholders have approved the merger agreement proposal at Paratek's special meeting of stockholders, in connection with the previously announced definitive agreement to be acquired by Gurnet Point Capital ("Gurnet Point") and Novo Holdings A/S ("Novo Holdings"). Final voting results for the special meeting will be disclosed on Form 8-K filed by Paratek with th

    $PRTK
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings A/S

    BOSTON, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. ("Paratek") (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats, today announced that a second leading independent proxy advisor Glass, Lewis & Co. ("Glass Lewis") has recommended that stockholders vote FOR the Company's previously announced definitive agreement to be acquired by Gurnet Point Capital ("Gurnet Point") and Novo Holdings A/S ("Novo Holdings"). The Glass Lewis recommendation follows the recent receipt of the recommendation from Institutional Shareholder Services Inc. (

    $PRTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

$PRTK
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$PRTK
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$PRTK
SEC Filings

See more

$PRTK
FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

See more
  • FDA Approval for NUZYRA issued to PARATEK PHARMS INC

    Submission status for PARATEK PHARMS INC's drug NUZYRA (SUPPL-10) with active ingredient OMADACYCLINE TOSYLATE has changed to 'Approval' on 05/27/2021. Application Category: NDA, Application Number: 209817, Application Classification: Efficacy

    $PRTK
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • FDA Approval for NUZYRA issued to PARATEK PHARMS INC

    Submission status for PARATEK PHARMS INC's drug NUZYRA (SUPPL-11) with active ingredient OMADACYCLINE TOSYLATE has changed to 'Approval' on 05/27/2021. Application Category: NDA, Application Number: 209816, Application Classification: Efficacy

    $PRTK
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • FDA Approval for NUZYRA

    Submission status for PARATEK PHARMS INC's drug NUZYRA (SUPPL-11) with active ingredient OMADACYCLINE TOSYLATE has changed to 'Approval' on 01/11/2021. Application Category: NDA, Application Number: 209817, Application Classification: Labeling

    $PRTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

$PRTK
Leadership Updates

Live Leadership Updates

See more
  • Paratek Pharmaceuticals Appoints Jeffrey Stein as Lead Independent Director of the Board

    BOSTON, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) today announced that the Company's independent directors of the Board have appointed Jeffrey Stein, PhD as its first Lead Independent Director, effective December 8, 2022. Dr. Stein was selected unanimously by the independent directors of the Board, in recognition of his extensive leadership experience, in-depth knowledge of Paratek and the business of the anti-infective industry, strong financial and operational track record, and demonstrated independent judgment, integrity and commitment to the role. Having served as a director of Paratek since its emergence as a public company in 2014, Dr. Stein

    $PRTK
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Lantheus Announces Appointment of Minnie Baylor-Henry as New Board Member

    NORTH BILLERICA, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("the Company") (NASDAQ:LNTH), today announced the appointment of Ms. Minnie Baylor-Henry, Esq., a renowned expert in regulatory affairs and compliance in the life sciences industry, to Lantheus' Board of Directors ("Board"), effective immediately. As an independent director, Ms. Baylor-Henry will serve as a member of the Board's Compensation Committee and the Science and Technology Committee. Following the appointment of Ms. Baylor-Henry, the Board will be comprised of nine directors, eight of whom are independent. "We are pleased to welcome Minnie Baylor-Henry, a highly respected authority in FDA law an

    $APYX
    $LNTH
    $PRTK
    $SCPH
    Medical/Dental Instruments
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Biotechnology: Pharmaceutical Preparations
  • Adaptive Phage Therapeutics Expands Board Following Series B Financing Led by Deerfield Management

    - Evan Loh, M.D., Jonathan Leff, and Jana Jensen, Ph.D., Appointed Directors of APT - Adaptive Phage Therapeutics, Inc. ("APT"), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced the appointment of Evan Loh, M.D., CEO of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), Jonathan Leff, Partner at Deerfield Management, and Jana Jensen, Ph.D., Chief Operating Officer at Deerfield Discovery and Development, to the company's Board of Directors. "We are delighted to welcome Evan, Jonathan, and Jana to APT's Board, as we expand our team following the successful completion of our $40.75 million Series B financing," said Greg Merril, A

    $PRTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

$PRTK
Financials

Live finance-specific insights

See more
  • Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue of $40.0 Million

    -- NUZYRA® (omadacycline) Net U.S. Sales of $33.8 Million from the Core Commercial Business, a 35% Increase Over Second Quarter 2022 --Previously Announced Agreement to be Acquired by Gurnet Point Capital and Novo Holdings A/S; Transaction Expected to Close in the Third Quarter BOSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), ("Paratek" or "the Company"), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today reported financial results and provided an update on corpora

    $PRTK
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Paratek Pharmaceuticals Announces First Quarter 2023 Revenue of $31.2 Million

    -- NUZYRA® (omadacycline) Generated Net U.S. Sales of $26.2 Million from the Core Commercial Business, a 32% Increase Over First Quarter 2022 -- Company Reiterates Full-Year Revenue Guidance of $143 to $158 Million -- Announces Full-Year R&D and SG&A Expense Guidance of $160 to $170 Million, Approximately $20 Million in Savings Over Annualized Fourth Quarter 2022 Spend Rate1, Enabled by Operational Efficiencies BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats fo

    $PRTK
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Paratek Pharmaceuticals to Report Financial Results for First Quarter 2023 on May 9

    BOSTON, May 01, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) today announced that the company will host a conference call and live audio webcast on Tuesday, May 9 at 4:30 p.m. EDT to report financial results for first quarter 2023.The audio webcast can be accessed under "Events and Presentations" in the Investor Relations section of the Company's website at www.ParatekPharma.com.Domestic investors wishing to participate in the call will dial: 800-920-3371 and international investors will dial: +1-212-231-2909. The conference ID is 22026760. Investors can also access the call at: https://viavid.webcasts.com/starthere.jsp?ei=1611304&tp_key=5fe62a51b9About Paratek Phar

    $PRTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

$PRTK
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more